After long road, Lilly's Alzheimer's imaging agent first to cross US finish line
This article was originally published in Clinica
Executive Summary
After initially being rejected last year by the US FDA, Lilly's non-therapeutic radiopharmaceutical Amyvid (florbetapir F 18 injection) gained regulators' blessing to enter the US market as a brain imaging agent of beta-amyloid plaques. It is intended for use in patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.